Clin2
NCT06126224Possibly a fitRecruiting

Testing KarXT for Alzheimer's-related psychosis

Psychosis Associated With Alzheimer's Disease

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
500 people
Ages
55 years to 90 years
Study type
Interventional

Who can take part

  • You are between 55 and 90 years old.
  • You have been diagnosed with possible or probable Alzheimer's disease.
  • You have had hallucinations or delusions for at least 2 months.
  • You have a family member or caregiver who can help with the study and spend about 10 hours a week with you.
  • You have not had a major depressive episode with psychotic features in the past year.
  • You do not have a history of bipolar disorder, schizophrenia, or schizoaffective disorder.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06887192Recruiting· Phase 2
Testing ML-007C-MA for Alzheimer's Psychosis

This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.

Phoenix, Arizona
NCT05511363Recruiting· Phase 3
Study of a new medicine for psychosis in Alzheimer's disease

This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.

Homewood, Alabama
NCT05980949Recruiting· Phase 3
Long-term safety study of KarXT for Alzheimer's psychosis

This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.

Homewood, Alabama
NCT06540833Recruiting· Phase 2
Study of ITI-1284 for psychosis in Alzheimer's disease

This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.

Anaheim, California
NCT06585787Recruiting· Phase 3
Testing KarXT for psychosis in Alzheimer’s disease

This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.

Chandler, Arizona
NCT06947941Recruiting· Phase 3
Testing karxt for psychosis in alzheimer's disease

This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.

Gilbert, Arizona

Hear when a new Psychosis Associated With Alzheimer's Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.